📊 SILO Key Takeaways
Is Silo Pharma, Inc. (SILO) a Good Investment?
Silo Pharma exhibits a fundamentally unsustainable business model with only $72.1K in revenue against $4.3M in operating losses, indicating an early-stage biotech without commercialized products or meaningful traction. The company's $4.7M quarterly cash burn consumes virtually its entire cash balance, providing less than one period of runway despite a debt-free balance sheet. The extreme negative operating margins (-5937%) and returns on equity (-67%) reflect a failed or severely distressed venture incapable of funding its own operations.
Why Buy Silo Pharma, Inc. Stock? SILO Key Strengths
- Zero debt with debt-to-equity ratio of 0.00 eliminates financial leverage risk
- Positive stockholders equity of $6.3M provides partial cushion against insolvency
- Exceptional liquidity ratios (current ratio 11.36x) reduce near-term default risk
SILO Stock Risks: Silo Pharma, Inc. Investment Risks
- Minimal revenue ($72.1K) coupled with $4.3M operating losses indicates complete lack of commercial viability
- Quarterly cash burn of $4.7M depletes $4.7M cash position within one period at current rates
- Pharmaceutical development failure pattern: no approved products, no clinical progress evident, no insider confidence (zero Form 4 filings)
- Operating cash flow negative $4.7M with no path to profitability apparent in current business structure
Key Metrics to Watch
- Quarterly revenue trends and commercialization milestone announcements
- Operating cash burn rate and remaining cash runway in months
- Clinical trial progression, regulatory approvals, or partnership announcements indicating viability
Silo Pharma, Inc. (SILO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 11.36x current ratio provides a solid financial cushion.
SILO Profit Margin, ROE & Profitability Analysis
SILO vs Healthcare Sector: How Silo Pharma, Inc. Compares
How Silo Pharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Silo Pharma, Inc. Stock Overvalued? SILO Valuation Analysis 2026
Based on fundamental analysis, Silo Pharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Silo Pharma, Inc. Balance Sheet: SILO Debt, Cash & Liquidity
SILO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Silo Pharma, Inc.'s revenue has grown significantly by 78% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.19 indicates the company is currently unprofitable.
SILO Revenue Growth, EPS Growth & YoY Performance
SILO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $18.0K | -$801.7K | $-0.12 |
| Q2 2025 | $18.0K | -$801.7K | $-0.19 |
| Q1 2025 | $18.0K | -$801.7K | $-0.23 |
| Q3 2024 | $18.0K | -$660.2K | $-0.21 |
| Q2 2024 | $18.0K | -$801.7K | $-0.31 |
| Q1 2024 | $18.0K | -$801.7K | $-0.28 |
| Q3 2023 | $18.0K | -$604.1K | N/A |
| Q2 2023 | $18.0K | -$604.1K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Silo Pharma, Inc. Dividends, Buybacks & Capital Allocation
SILO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Silo Pharma, Inc. (CIK: 0001514183)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SILO
What is the AI rating for SILO?
Silo Pharma, Inc. (SILO) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SILO's key strengths?
Claude: Zero debt with debt-to-equity ratio of 0.00 eliminates financial leverage risk. Positive stockholders equity of $6.3M provides partial cushion against insolvency.
What are the risks of investing in SILO?
Claude: Minimal revenue ($72.1K) coupled with $4.3M operating losses indicates complete lack of commercial viability. Quarterly cash burn of $4.7M depletes $4.7M cash position within one period at current rates.
What is SILO's revenue and growth?
Silo Pharma, Inc. reported revenue of $72.1K.
Does SILO pay dividends?
Silo Pharma, Inc. does not currently pay dividends.
Where can I find SILO SEC filings?
Official SEC filings for Silo Pharma, Inc. (CIK: 0001514183) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SILO's EPS?
Silo Pharma, Inc. has a diluted EPS of $-0.50.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SILO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Silo Pharma, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SILO stock overvalued or undervalued?
Valuation metrics for SILO: ROE of -67.0% (sector avg: 15%), net margin of -5,863.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SILO stock in 2026?
Our dual AI analysis gives Silo Pharma, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SILO's free cash flow?
Silo Pharma, Inc.'s operating cash flow is $-4.7M, with capital expenditures of N/A. FCF margin is -6,464.9%.
How does SILO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5,863.5% (avg: 12%), ROE -67.0% (avg: 15%), current ratio 11.36 (avg: 2).